Skip to main content
. 2024 May 15;8(13):3507–3518. doi: 10.1182/bloodadvances.2024012800

Figure 2.

Figure 2.

MTNKN subtypes with CNS relapse and outcomes. (A) Frequency of MTNKN subtypes is depicted with number of patients displayed above each bar. Kaplan-Meier estimates for PFS and OS after initial diagnosis are shown in panels B and C, respectively. Four patients were excluded from PFS calculation due to absence of data on time to initial progression. Cumulative incidence of CNS relapse and OS after CNS relapse are shown by reverse and standard Kaplan-Meier estimate in panels D and E-F, respectively. Median OS after CNS relapse is indicated by dashed line (F). For all Kaplan-Meier curves, hashmarks denote censored patients, and shading indicates 95% CI. AITL, angioimmunoblastic T-cell lymphoma; ALKu, ALK status unknown; ANKL, aggressive NK-cell lymphoma; ATLL, adult T-cell leukemia/lymphoma; CLD-NK, chronic lymphoproliferative disorder of NK-cells; HSTCL, hepatosplenic T-cell lymphoma; MEITL, monomorphic epitheliotropic intestinal T-cell lymphoma; T-IOL, T-cell intraocular lymphoma; T-LGL, T-cell large granular lymphocytic leukemia; T-PLL, T-cell prolymphocytic leukemia; TCL, T-cell lymphoma; TFH-TCL, T-follicular helper T-cell lymphoma.